Search

Displaying results 3671 - 3680 of 5449 in total
  1. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    It is also known as HSPs, which are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation.

  2. Drug

    Mesterolone

    go.drugbank.com/drugs/DB13587
    Investigational

    It is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen.

    Products: RESTORE TABLET 25 mg, PROVIRON 25 MG TABLET, 20 ADET
  3. Drug

    Acetyl hexapeptide-3

    go.drugbank.com/drugs/DB11709
    Investigational

    Argireline has been used in trials studying the treatment of wrinkles.

    Mixtures: Conopeptide Deer Bone Collagen Nano Instant Essence Filling Set
  4. Drug

    Eleclazine

    go.drugbank.com/drugs/DB12394
    Investigational

    Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.

  5. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234220] It has also been observed to be efficacious independent of food intake.[A234220]

    Products: KI-CAB® TABLETAS 50 MG
  6. Drug

    Hexamethonium

    go.drugbank.com/drugs/DB08960
    Experimental

    It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely … It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.

  7. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pu...

  8. Drug

    Resolvin E1

    go.drugbank.com/drugs/DB13105
    Investigational

    Resolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).

  9. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    While artemether results in rapid defervescence, parasite clearance, and clinical improvement, it also has a relatively high recrudescence rate when used as monotherapy. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  10. Drug

    Crotalus scutulatus antivenin

    go.drugbank.com/drugs/DB13891
    Approved

    It is intravenously administered to limit systemic toxicity [FDA label], [L2857], [L2858]. … Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom.